On August 21, 2026 Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, reported that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZEGFROVY (sunvozertinib) in non-small cell lung cancer (NSCLC) will be presented at the 2026 World Conference on Lung Cancer (WCLC) from September 12 to 15 in Seoul, Republic of Korea.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ZEGFROVY is approved in China and the U.S. for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. In addition, with positive results from WU-KONG28, a multinational randomized Phase 3 study in treatment naïve patients, the Supplemental New Drug Application (sNDA) of ZEGFROVY as first-line treatment has been submitted to China Center for Drug Evaluation (CDE) and the US Food and Drug Administration (FDA). On July 14, Dizal announced that it entered into an exclusive license agreement granting AstraZeneca global rights to develop and commercialize ZEGFROVY. The transaction is expected to close in the second half of 2026.
At WCLC 2026, Dizal will present the latest findings from a study evaluating ZEGFROVY as adjuvant treatment in patients with resected stage IB-IIIB EGFR exon20ins NSCLC. Promising efficacy results strengthen its potential as an earlier treatment option. No new safety signals have been observed. Based on these findings, a randomized pivotal study is ongoing.
In addition, Dizal will report updated data from a Phase 2 study evaluating ZEGFROVY in combination with Anlotinib as first-line treatment for NSCLC with EGFR sensitizing mutations and co-mutations. This oral chemotherapy-free combination regimen continues to exhibit robust anti-tumor activity and a manageable safety profile.
The details of the presentation are shown below:
Lead Author
Abstract Title
Presentation Details
Prof. Chang Chen
Efficacy and Safety of Sunvozertinib as Adjuvant
Treatment in Resected Stage IB-IIIB EGFR Exon 20
Insertion Mutated NSCLC
Abstract Number: P1.159
Poster Session
10:30 AM – 12:00 PM (KST /
UTC +9), Sep 13, 2026
Prof. Yongchang Zhang
Sunvozertinib Plus Anlotinib as First-line Treatment for
NSCLC with EGFR Sensitive Mutations and Co-
mutations: Updated Phase II Data
Abstract Number: P3.207
Poster Session
9:30 AM – 11:00 AM (KST /
UTC +9), Sep 15, 2026
About ZEGFROVY (sunvozertinib)
ZEGFROVY is an irreversible EGFR inhibitor targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by the results of WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication. The sNDA for ZEGFROVY as first-line treatment in NSCLC patients with EGFR exon20ins has been submitted to the China Center for Drug Evaluation (CDE) and US Food and Drug Administration (FDA), supported by WU-KONG28 study results. Both China CDE and the US FDA have granted Breakthrough Therapy Designation to ZEGFROVY in this setting.
In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins. ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse events) were Grade 1/2 in nature and clinically manageable.
(Press release, Dizal Pharma, AUG 21, 2026, View Source [SID1234670278])